Articles tagged with: GDC-0941
NewsFlash »
GDC-0941 May Be Active In Multiple Myeloma – Results of a recent preclinical study suggest that the investigational drug GDC-0941, which is being developed by the biotech company Genentech, may have anti-myeloma activity and may increase the activity of Revlimid (lenalidomide) and dexamethasone (Decadron). Like perifosine, another investigational myeloma treatment, GDC-0941 inhibits an enzyme in cancer cells known as phosphoinositide 3-kinase (PI3K). By inhibiting PI3K, GDC-0941 disrupts the cell division cycle and causes cancer cell death. It is being investigated as a treatment for a variety of different cancers, including breast cancer and lung cancer. Based on their findings, the researchers recommend that GDC-0941 be further developed as a potential treatment for myeloma. For more information, please see the study in the journal Oncogene (abstract).
Phase 1 Clinical Trial To Study CUDC-907 In Multiple Myeloma And Lymphoma Patients – The pharmaceutical company Curis (NASDAQ:CRIS) has launched a Phase 1 trial of CUDC-907 in patients with relapsed and refractory multiple myeloma or lymphoma. Patients must have received at least two prior therapies to be eligible for the study. CUDC-907 is a multi-targeted agent that inhibits both PI3K and histone deacetylase (HDAC) in cancer cells. Other HDAC inhibitors that are being investigated as potential treatments for multiple myeloma include Zolinza (vorinostat), panobinostat, and ricolinostat (ACY-1215). For more information, including trial locations, please see the clinical trial description.
LLS Teleconference About Latest Myeloma Research From ASH – On January 29, the Leukemia & Lymphoma Society (LLS) will sponsor a free teleconference call about the latest myeloma research from the American Society of Hematology (ASH) annual meeting. Dr. Kenneth Anderson, director of the Jerome Lipper Myeloma Center at the Dana-Farber Cancer Institute in Boston, will lead the program, which will run from noon till 1:30 p.m. Eastern Time. Dr. Anderson will speak about current and emerging myeloma treatments, the role of clinical trials in the development of myeloma treatment, and advances in the management of treatment side effects. For more information or to register, please see the LLS website.
News»
This year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday and goes through Tuesday, is being held in Chicago.
On the first day of the meeting, there was only one talk related to multiple myeloma. During an afternoon education session, in which current practice and recent research results are reviewed, Dr. Raphael Fonseca from the Mayo Clinic in Scottsdale, Arizona, spoke about high-risk multiple myeloma.
The second day of the meeting included a morning and an afternoon session in which myeloma researchers presented their findings in the form …
News»
The 47th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 3, through Tuesday, June 7, in Chicago.
More than 30,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. This year’s meeting will primarily focus on the theme of “Patients, Pathways, Progress.”
The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists over 40 myeloma-based abstracts.
The Myeloma Beacon will be …
